- Home
- DRUG vs CYRX Comparison
DRUG vs CYRX Comparison
Compare DRUG & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- CYRX
- Stock Information
- Founded
- DRUG 2019
- CYRX 1999
- Country
- DRUG United States
- CYRX United States
- Employees
- DRUG N/A
- CYRX N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- CYRX Health Care
- Exchange
- DRUG Nasdaq
- CYRX Nasdaq
- Market Cap
- DRUG 233.2M
- CYRX 277.5M
- IPO Year
- DRUG N/A
- CYRX N/A
- Fundamental
- Price
- DRUG $27.31
- CYRX $6.37
- Analyst Decision
- DRUG Strong Buy
- CYRX Strong Buy
- Analyst Count
- DRUG 6
- CYRX 8
- Target Price
- DRUG $83.25
- CYRX $10.75
- AVG Volume (30 Days)
- DRUG 19.6K
- CYRX 458.0K
- Earning Date
- DRUG 08-13-2025
- CYRX 08-05-2025
- Dividend Yield
- DRUG N/A
- CYRX N/A
- EPS Growth
- DRUG N/A
- CYRX N/A
- EPS
- DRUG N/A
- CYRX N/A
- Revenue
- DRUG N/A
- CYRX $232,134,000.00
- Revenue This Year
- DRUG N/A
- CYRX N/A
- Revenue Next Year
- DRUG N/A
- CYRX $9.63
- P/E Ratio
- DRUG N/A
- CYRX N/A
- Revenue Growth
- DRUG N/A
- CYRX 11.75
- 52 Week Low
- DRUG $0.93
- CYRX $4.58
- 52 Week High
- DRUG $79.02
- CYRX $9.93
- Technical
- Relative Strength Index (RSI)
- DRUG 41.95
- CYRX 48.30
- Support Level
- DRUG $27.69
- CYRX $6.53
- Resistance Level
- DRUG $28.74
- CYRX $6.98
- Average True Range (ATR)
- DRUG 1.29
- CYRX 0.47
- MACD
- DRUG 0.14
- CYRX -0.01
- Stochastic Oscillator
- DRUG 39.29
- CYRX 56.38
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.